Picture of CSL logo

CSL CSL Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Momentum

Relative Strength (%)
1m+5.04%
3m+4.18%
6m-0.06%
1yr-5.68%
Volume Change (%)
10d/3m+18.48%
Price vs... (%)
52w High-4.7%
50d MA+3.89%
200d MA+6.8%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)27.97
PEG Ratio (f)2.01
EPS Growth (f)16.13%
Dividend Yield (f)1.6%
Valuation (ttm)IndustryMarket
Price to Book Value5.45
Price to Tang. Book131.91
Price to Free Cashflow80.83
Price to Sales6.6
EV to EBITDA24.11

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital10.89%
Return on Equity15.05%
Operating Margin25.02%

Financial Summary

Year End 30th JunUnit201920202021202220232024E2025ECAGR / Avg
Total Revenue$m8,538.69,150.810,31010,561.913,31014,713.1615,924.8110.95%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+11.47+8.39+8.42-6.4-3.44+23.2+16.07n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of CSL EPS forecast chart

Profile Summary

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.

Directors

Last Annual
June 30th, 2023
Last Interim
December 31st, 2023
Incorporated
April 1st, 1991
Public Since
June 8th, 1994
No. of Shareholders
248,407
No. of Employees
32,065
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
483,093,257

CSL Share Price Performance

Upcoming Events for CSL

Full Year 2024 CSL Ltd Earnings Release

CSL Ltd Annual Shareholders Meeting

Similar to CSL

Picture of Acrux logo

Acrux

au flag iconAustralian Stock Exchange - SEATS

Picture of AFT Pharmaceuticals logo

AFT Pharmaceuticals

au flag iconAustralian Stock Exchange - SEATS

Picture of Althea group logo

Althea group

au flag iconAustralian Stock Exchange - SEATS

Picture of Anatara Lifesciences logo

Anatara Lifesciences

au flag iconAustralian Stock Exchange - SEATS

Picture of Argent BioPharma logo

Argent BioPharma

au flag iconAustralian Stock Exchange - SEATS

FAQ